HC Wainwright Predicts Invivyd FY2030 Earnings

Invivyd, Inc. (NASDAQ:IVVD) – Equities researchers at HC Wainwright issued their FY2030 earnings per share (EPS) estimates for shares of Invivyd in a research note issued to investors on Friday, January 23rd. HC Wainwright analyst P. Trucchio anticipates that the company will earn $1.16 per share for the year. HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for Invivyd’s current full-year earnings is ($1.64) per share.

Other equities analysts have also issued reports about the company. D. Boral Capital reiterated a “hold” rating on shares of Invivyd in a research report on Tuesday, November 25th. D Boral Capital lowered shares of Invivyd from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 25th. Cantor Fitzgerald began coverage on shares of Invivyd in a report on Monday, October 6th. They issued an “overweight” rating and a $10.00 price target for the company. Zacks Research upgraded shares of Invivyd from a “strong sell” rating to a “hold” rating in a report on Thursday, November 13th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Invivyd in a research report on Monday, December 29th. Three investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Invivyd presently has an average rating of “Hold” and a consensus target price of $8.00.

Invivyd Stock Down 4.5%

Shares of NASDAQ IVVD opened at $2.11 on Monday. Invivyd has a twelve month low of $0.35 and a twelve month high of $3.07. The stock has a market cap of $491.88 million, a price-to-earnings ratio of -4.49 and a beta of 0.61. The company’s fifty day moving average is $2.43 and its 200-day moving average is $1.64.

Invivyd (NASDAQ:IVVD) last released its earnings results on Thursday, November 6th. The company reported ($0.06) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.01). The company had revenue of $13.13 million during the quarter, compared to analyst estimates of $12.00 million. Invivyd had a negative net margin of 119.63% and a negative return on equity of 92.97%.

Insider Buying and Selling at Invivyd

In related news, Director Kevin F. Mclaughlin acquired 50,000 shares of the company’s stock in a transaction dated Wednesday, November 19th. The shares were bought at an average price of $2.50 per share, for a total transaction of $125,000.00. Following the purchase, the director directly owned 50,000 shares in the company, valued at approximately $125,000. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 25.40% of the stock is owned by company insiders.

Institutional Investors Weigh In On Invivyd

Institutional investors and hedge funds have recently modified their holdings of the company. RA Capital Management L.P. bought a new position in Invivyd during the third quarter worth about $18,831,000. ADAR1 Capital Management LLC acquired a new stake in shares of Invivyd in the third quarter valued at approximately $8,108,000. Vanguard Group Inc. lifted its position in shares of Invivyd by 46.7% in the third quarter. Vanguard Group Inc. now owns 5,762,894 shares of the company’s stock valued at $6,339,000 after buying an additional 1,834,970 shares during the last quarter. Boothbay Fund Management LLC bought a new position in shares of Invivyd during the 3rd quarter worth approximately $894,000. Finally, AQR Capital Management LLC increased its holdings in shares of Invivyd by 2,051.0% during the 1st quarter. AQR Capital Management LLC now owns 410,711 shares of the company’s stock worth $249,000 after acquiring an additional 391,617 shares during the last quarter. 70.36% of the stock is owned by institutional investors.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.